Article Sidebar

Issue: No. 3 (2026)
Section: Articles
Date Published: 28/10/2026
Views 0
How to Cite
Nguyen, T. T., Nguyen, T. T. N., Nguyen, T. T. T. H., Nguyen, T. T. L., & Nguyen, T. V. (2026). Clinical Microbiological Characteristics and Antimicrobial Susceptibility Patterns of Proteus spp. Isolated from Cancer Patients at K Hospital. Journal of Disaster Medicine and Burn Injuries, 3. https://jbdmp.vn/index.php/yhthvb/article/view/608

Clinical Microbiological Characteristics and Antimicrobial Susceptibility Patterns of Proteus spp. Isolated from Cancer Patients at K Hospital

Nguyen Thanh Tung1, Nguyen Thi Tuyet Nga2, Nguyen Thi Thanh Thanh Huyen2, Nguyen Thi Thuy Lien2, Nguyen Thanh Viet2,
1 Vietnam Tan Trieu National Cancer Hospital
2 Le Huu Trac National Burn Hospital

Main Article Content

Abstract

Background: Proteus spp. are opportunistic Gram-negative pathogens associated with a wide range of healthcare-associated infections, particularly among immunocompromised patients. Continuous surveillance of antimicrobial susceptibility patterns is essential for guiding empirical antibiotic therapy and supporting antimicrobial stewardship programs in oncology settings.
Objective: To describe the clinical microbiological characteristics and antimicrobial susceptibility profiles of Proteus spp. isolated from cancer patients at K Hospital.
Methods: A retrospective cross-sectional study was conducted on 20 Proteus spp. isolates recovered from clinical specimens of cancer patients treated at K Hospital from January 2025 to June 2026. Demographic characteristics, specimen types, bacterial species, and antimicrobial susceptibility data were collected and analyzed using R software version 4.4.1.
Results: The median age of patients was 66 years (IQR: 57 - 72), and 50.0% were male. Proteus mirabilis accounted for 90.0% of all isolates. Urine was the most common specimen type (35.0%). High resistance rates were observed for nitrofurantoin [100.0%], amoxicillin (88.9%), ampicillin (88.2%), and trimethoprim/sulfamethoxazole (77.8%). All tested isolates were susceptible to meropenem, ertapenem, piperacillin/tazobactam, and ceftazidime.
Conclusions: Proteus spp. isolated from cancer patients at K Hospital exhibited high resistance rates to several commonly used antibiotics, whereas broad-spectrum agents, including carbapenems and piperacillin/tazobactam, retained excellent antimicrobial activity. These findings provide valuable data for local antimicrobial resistance surveillance and may assist clinicians in selecting appropriate antimicrobial therapy in oncology practice.

Keywords

Proteus spp., Proteus mirabilis, antimicrobial resistance, cancer patients, clinical microbiology

Article Details

References

1. Hamilton AL, Kamm MA, Ng SC, Morrison M. Proteus spp. as Putative Gastrointestinal Pathogens. Clinical microbiology reviews. 2018;31(3):e00085-17.
2. Drzewiecka D. Significance and Roles of Proteus spp. Bacteria in Natural Environments. Microbial ecology. 2016;72(4):741-58.
3. Zafar U, Taj MK, Nawaz I, Zafar A, Taj I. Characterization of Proteus mirabilis Isolated from Patient Wounds at Bolan Medical Complex Hospital, Quetta. Jundishapur J Microbiol. 2019;12(7):e87963.
4. Afifi M, Abdelrazek M, Nasr Y, Amasha M, Shoela E, Shalaby R, et al. Proteus mirabilis in ICU Patients: Prevalence, Risk Factors, and Future Expectations of Bloodstream Infections. Cureus. 2025;17(8):e91083.
5. Hassuna NA, Kotb DN, Lami M, Abdelrahim SS. Characterization of antimicrobial resistance among Proteus mirabilis isolates from catheter-associated urinary tract infections and non-catheter-associated urinary tract infections in Egypt. BMC infectious diseases. 2025;25(1):767.
6. Almutawif YA, Eid HMA. Prevalence and antimicrobial susceptibility pattern of bacterial uropathogens among adult patients in Madinah, Saudi Arabia. BMC infectious diseases. 2023;23(1):582.
7. Gallis HA. Infections in elderly cancer patients. Clinics in geriatric medicine. 1987;3(3):549-60.
8. Chan WL, Li VWK, Hou H, Kwong D. Infection risk in older patients with cancer undergoing chemotherapy: A real-world analysis. Journal of Geriatric Oncology. 2025;16(8, Supplement):102510.
9. Çeken S, Yılmaz N, Hekimoğlu CH, Yapar Toros G, Güleşen A, Savaş EM, et al. Bloodstream infections in older cancer patients: epidemiology and risk factors for mortality. Journal of infection in developing countries. 2025;19(8):1205-15.
10. Yang A, Tian Y, Li X. Unveiling the hidden arsenal: new insights into Proteus mirabilis virulence in UTIs. Front Cell Infect Microbiol. 2024;14:1465460.
11. Schaffer JN, Pearson MM. Proteus mirabilis and Urinary Tract Infections. Microbiology spectrum. 2015;3(5). DOI 10.1128/microbiolspec.UTI-0017-2013.
12. Wang JT, Chen PC, Chang SC, Shiau YR, Wang HY, Lai JF, et al. Antimicrobial susceptibilities of Proteus mirabilis: a longitudinal nationwide study from the Taiwan surveillance of antimicrobial resistance (TSAR) program. BMC infectious diseases. 2014;14:486.
13. Danilo de Oliveira W, Lopes Barboza MG, Faustino G, Yamanaka Inagaki WT, Sanches MS, Takayama Kobayashi RK, et al. Virulence, resistance and clonality of Proteus mirabilis isolated from patients with community-acquired urinary tract infection (CA-UTI) in Brazil. Microbial pathogenesis. 2021;152:104642.
14. Joseph AS, Manjari CVS, Lathakumari RH, Vajravelu LK. Emergence of β-lactamase-producing Proteus mirabilis in clinical settings: A genotypic investigation of resistance mechanisms and carbapenemase genes bla (NDM-1) and bla (KPC-2). Biotechnology notes (Amsterdam, Netherlands). 2025;6:177-82.
15. Hafiz TA, Alghamdi GS, Alkudmani ZS, Alyami AS, AlMazyed A, Alhumaidan OS, et al. Multidrug-Resistant Proteus mirabilis Infections and Clinical Outcome at Tertiary Hospital in Riyadh, Saudi Arabia. Infection and Drug Resistance. 2024;17:571-81.